Emcure Q1 FY27: Revenue up 22.8%, PAT grows 36.2% on strong international business

Mgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF Explain this filing

EMCURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.6%1-day move

₹1950.00

prior close

₹1927.70

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.0-0.7-0.2-0.0+1.6+2.4+2.5+2.8+2.9-3.7————

Up moveDown movePending

AI summary

Emcure posted Q1 FY27 revenue of ₹25,804 Mn, up 22.8% YoY, led by international business at 58% of mix and up 34.2%. Domestic grew 10.2%. EBITDA margin improved 50 bps to 19.7%; PAT margin rose 110 bps to 11.3% with PAT at ₹2,925 Mn, up 36.2%. RoCE stood at 23.4% with net debt to TTM EBITDA at 0.7x. Leadership: Satish Mehta to take over as Chairman post-AGM; Samit Mehta named COO, and will lead Gennova as CEO after it became a wholly-owned subsidiary. New MSD licensing deal signed for alimatravir PrEP candidate.

Likely market impact

Strong all-round quarter with margin expansion, low leverage, and smooth promoter-family succession; likely positive for sentiment and stock price.